Treatment with Welireg — now approved by the FDA — helped shrink and stabilize tumors from metastatic renal cell carcinoma with minimal side effects, a patient told CURE®.
The Food and Drug Administration (FDA) recently approved Welireg (belzutifan) for patients with advanced renal cell carcinoma (RCC) who experienced progression after receiving a PD-1 and/or PD-L1 checkpoint inhibitor, and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
According to the National Cancer Institute, Welireg is a type of drug that blocks specific proteins, which can help destroy tumors. The drug may also help prevent new blood vessels from growing, which tumors need in order to survive.
This FDA approval arrived following results from the LITESPARK-005 trial, which compared the objective response rates (ORR; patients who had a partial or complete response to treatment) of Welireg and Afinitor (everolimus). The trial analyzed these two drugs in patients with advanced clear cell RCC, which is the most common type of kidney cancer, according to the American Cancer Society.
Mark Hilz received a diagnosis of stage 4 RCC in 2015, four years after the original clear cell RCC was removed with his left kidney. He was told there were still remaining tumors on his adrenal gland and lungs. Even after several treatments, including radiation, surgery, high-dose interleukin-2 (IL2) and treatment with Avastin (bevacizumab) that he said was discontinued due to side effects, Hilz was still left with more than 30 present tumors throughout his body.
“(For) my first treatment (of Welireg), I was only on for 70 days, but I actually started having tumor reductions (before the) 90-day period in between scans,” Hilz said. “Plus, it stopped all tumor growth everywhere else. I had additional tumor reductions on my next 90-day scan, and then completely stable everywhere else.
“After eight years of not finding anything from a systemic therapy that would work, having this available for you is (a) pretty good deal. And also, to think (Welireg) was not even available when I had the initial cancer, to be looking for a systemic therapy that showed some promise for me for eight years, being stage four, and then finally finding something — especially when you're aware you're starting to really run out of options, it has been a wonderful lifesaver for me.”
Trial findings, which were presented earlier this year at the European Society of Medical Oncology Annual Congress (ESMO), showed that at a median follow-up of 18.4 months, patients treated with Welireg experienced an ORR of 21.9% compared with 3.5% among patients treated with Afinitor, and 12-month progression-free survival (PFS; the time a patient lives without their disease spreading or worsening) rates of 33.7% on Welireg versus 17.6% with Afinitor, and 18-month PFS rates of 22.5% and 9%, respectively.
The most common side effects of Welireg, occurring in at least 25% of patients, included decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium and increased aspartate aminotransferase, the FDA reported in its announcement of the approval.
In terms of Welireg’s side effects, Hilz said he experienced anemia and fatigue, but stated that drinking coffee has helped reduce the feeling of both side effects.
“I have a couple of cups of coffee, (I) don't really feel the anemia much. … (and) a couple of cups of coffee to offset a little bit of fatigue,” Hilz explained. “But out of all the patients who probably shouldn't have fatigue, no adrenal glands, classic anemia, you would think I would be affected more than most.”
The quality of life — an important factor for patients — was found to be most beneficial for patients receiving Welireg.
“Patients will likely find that Welireg is much more tolerable than any TKI they may have been on before. And they don't have to worry about autoimmune side effects which is a concern with immune checkpoint inhibitors,” Dr. James Brugarolas, founding director of the kidney cancer program at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center and an investigator who helped develop the drug, told CURE®. “Welireg is also an option for patients with cardiovascular disease and autoimmune conditions who cannot take TKIs or immune checkpoint inhibitors.”
After Hilz received high-dose IL2 in the hospital each week and visited the clinic to receive Avastin every two weeks, three pills of Welireg before bed offered him “a very normal lifestyle.”
“I'm fully employed (as a) chief operating officer (and) I enjoy working. (Welireg) doesn’t really affect my work,” Hilz said. “The way I like to tell everybody is all I have to do to treat myself … is go to bed and take three pills.
“I mean, that is an amazing thing from a lifestyle perspective, right? You can go on trips, you can do whatever you want, you don't have to worry about going in for an infusion every two weeks.”
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.